SCOUT DS™ Clinical Performance
The SCOUT DS system outperforms FPG and A1C
A study utilizing a SCOUT DS prototype system to screen 351 subjects with risk factors for type 2 diabetes showed the SCOUT DS prototype significantly outperformed both FPG and A1C by detecting 29% more patients with type 2 and pre-diabetes than FPG and 17% more cases than A1C.
Superior performance detecting impaired glucose tolerance
Further evaluation of a sub-cohort of the clinical data showed the the SCOUT DS prototype device was able to identify 78% more individuals with IGT than the FPG test and 47% more than the A1C test. This performance reinforces skin AGEs as a highly sensitive summary metric for early diabetes screening.
Source:
• Maynard J, Rohrscheib M, Way J, Nguyen C, Ediger M. Noninvasive type 2 diabetes screening, superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007;30:1120-1124.
Caution: Federal law restricts the SCOUT DS system to investigational use only.